Therefore, the strategy described here for studying ADAM17 mutations could be used to analyze the impacts of individual ARID1B and CSMD1 mutations identified in metastatic SS on metastasis-associated phenotypes. The gene discussed is ADAM17; the disease is synovial sarcoma.